well, you are making the assumption. If they were diagnosed 5...

well, you are making the assumption. If they were diagnosed 5 months prior then patient D-F lived 11 months which is bang on average.

Fact is the share price is down from the 23rd October announcement. 11 patient trial is tiny. 5 of the patients showed no disease control. Only a couple showed longevity but who knows if that is due to factors other than the drug.

One patient surviving up to 18 months is nice but it does not point toward a wonder drug. I dont see anything that points toward SoC.

Only patient A and B showed good results but the data is far too small to matter at this stage. That still leaves 9 patients with no benefit over current survival rates.

Another study in 60 patients "The objective was to assess 2-year survival and quality of life in GBM patients who underwent primary surgery followed by chemo-radiotherapy and 6-month adjuvant chemotherapy with temozolomide."

"60 patients with GBM were analyzed, male to female ratio was 1.6:1. Patients most commonly presented with headache. Most common tumour site is the frontal lobe. The median overall survival (OS) was 10 months. The 1-year and 2-year survival rates were 30% and 6.7%, respectively."

Only 3% to 5% of patients survive more than three years, and reports of survival exceeding five years are sporadic